RESMED INC RMD

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus NYSE

We are a global leader in digital health and cloud-connected medical devices. We design innovative technology to empower people to live happier, healthier lives. Our artificial intelligence, or AI, powered digital health solutions, cloud-connected devices and intelligent software are designed to make home healthcare more personalized, accessible and effective. By enabling better care, our products improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems.

Following our formation in 1989, we commercialized a continuous positive airway pressure, or CPAP, treatment for obstructive sleep apnea, or OSA, which was the first successful non-invasive treatment for OSA. CPAP systems deliver pressurized air, typically through a mask, to prevent collapse of the upper airway during sleep. Since the development of CPAP, we have expanded our business by developing or acquiring a number of innovative products and solutions for a broad range of sleep and related breathing health disorders including technologies to be applied in medical and consumer products, life support and ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, and dental devices. In addition, we are a leading provider of cloud-based health applications, software and devices designed to provide connected care, enabling clinicians to manage more patients efficiently and effectively, as well as enabling and encouraging patients' long-term adherence to and satisfaction with their therapy.

Last close 228.35 2026-09-04
Market cap $32.94B 2026-06-30 share count
52-week range 180.26 - 284.87

Valuation FY2026 figures against the last close

P/S5.8x
P/E21.9x
P/FCF20.0x
EV/EBITDA15.4x
Dividend yield1.1%
Diluted EPS10.43

Annual financial statements

Income statement

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue $5.65B$5.15B$4.69B$4.22B$3.58B$3.20B$2.96B$2.61B$2.34B$2.07B
Cost of revenue $2.20B$2.09B$2.03B$1.87B$1.55B$1.36B$1.24B$1.11B$1.01B$865.0M
Gross profit $3.45B$3.05B$2.66B$2.36B$2.02B$1.84B$1.72B$1.49B$1.33B$1.20B
R&D $378.3M$331.3M$307.5M$287.6M$253.6M$225.3M$201.9M$180.7M$155.1M$144.5M
SG&A $1.12B$993.0M$917.1M$874.0M$737.5M$670.4M$676.7M$645.0M$600.4M$554.0M
Total operating expenses $1.57B$1.37B$1.34B$1.22B$1.02B$935.4M$908.1M$914.8M$793.1M$775.9M
Operating income $1.89B$1.69B$1.32B$1.13B$1.00B$903.7M$809.7M$579.3M$541.8M$425.8M
Interest expense $47.4M$22.3M$23.6M$39.4M$36.2M$28.4M$28.2M
Pre-tax income $1.92B$1.68B$1.26B$1.10B$960.5M$883.7M$733.1M$518.8M$521.3M$418.7M
Income tax $396.1M$276.8M$243.8M$204.1M$181.0M$409.2M$111.4M$114.3M$205.7M$76.5M
Net income $1.52B$1.40B$1.02B$897.6M$779.4M$474.5M$621.7M$404.6M$315.6M$342.3M
EPS, basic 10.479.556.946.125.343.274.312.832.212.42
EPS, diluted 10.439.516.926.095.303.244.272.802.192.40
Shares, diluted (wtd. avg.) $146.1M$147.3M$147.6M$147.5M$147.0M$146.5M$145.7M$144.5M$144.0M$142.5M

Balance sheet

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents $1.47B$1.21B$238.4M$227.9M$273.7M$295.3M$463.2M$147.1M$188.7M$821.9M
Receivables $1.04B$939.5M$837.3M$704.9M$576.0M$614.3M$474.6M$528.5M$483.7M$450.5M
Inventory $945.8M$927.7M$822.2M$998.0M$743.9M$457.0M$416.9M$349.6M$268.7M$268.3M
Total current assets $4.32B$3.51B$2.36B$2.37B$1.93B$1.57B$1.52B$1.15B$1.07B$1.64B
Property, plant and equipment $581.8M$550.8M$548.0M$537.9M$498.2M$463.5M$417.3M$387.5M$386.6M$394.2M
Goodwill $2.91B$3.05B$2.84B$2.77B$1.94B$1.93B$1.89B$1.86B$1.07B$1.06B
Other intangibles $452.7M$464.9M$485.9M$552.3M$345.9M$392.6M$448.2M$522.0M$215.2M$261.8M
Total assets $8.97B$8.17B$6.87B$6.75B$5.10B$4.73B$4.59B$4.11B$3.06B$3.47B
Accounts payable $308.9M$278.2M$237.7M$150.8M$159.2M$138.0M$135.8M$115.7M$92.7M$92.8M
Short-term debt $259.9M$9.9M$9.9M$9.9M$9.9M$12.0M$12.0M$12.0M$11.5M
Total current liabilities $1.40B$1.02B$910.7M$758.5M$689.3M$911.8M$602.8M$556.0M$511.2M$360.1M
Long-term debt $399.4M$658.4M$697.3M$1.43B$765.3M$643.4M$1.16B$1.26B$270.0M$1.08B
Total liabilities $2.38B$2.21B$2.01B$2.62B$1.74B$1.84B$2.09B$2.04B$1.00B$1.51B
Retained earnings $7.26B$6.08B$4.99B$4.25B$3.61B$3.08B$2.83B$2.44B$2.43B$2.32B
Total equity $6.59B$5.97B$4.86B$4.13B$3.36B$2.89B$2.50B$2.07B$2.06B$1.96B

Cash flow

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Operating cash flow $1.81B$1.75B$1.40B$693.3M$351.1M$736.7M$802.3M$459.1M$505.0M$414.1M
Depreciation and amortisation $201.3M$198.5M$176.9M$165.2M$159.6M$156.8M$154.8M$150.8M$120.0M$112.2M
Stock-based compensation $104.3M$91.7M$80.2M$71.1M$65.3M$63.9M$57.6M$52.1M$48.4M$45.9M
Capital expenditure $156.3M$89.9M$99.5M$119.7M$134.8M$102.7M$95.3M$68.7M$62.6M$62.2M
Investing cash flow -$545.2M-$200.0M-$269.8M-$1.16B-$229.9M-$158.5M-$179.9M-$1.08B-$101.8M-$81.9M
Financing cash flow -$1.01B-$606.3M-$1.12B$422.9M-$128.4M-$764.6M-$317.3M$580.6M-$1.03B-$262.9M
Dividends paid $349.7M$310.9M$282.3M$258.3M$245.3M$226.7M$225.1M$211.7M$199.5M$186.3M
Buybacks $700.0M$300.0M$150.0M$0$0$22.8M$53.8M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000943819-26-000047.

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $116.27B 36.1x 11.2%
MMM 3M CO $86.93B 28.1x 1.5%
BSX BOSTON SCIENTIFIC CORP $69.27B 24.6x 19.9%
BDX BECTON DICKINSON & CO $50.32B 31.7x 8.2%
DXCM DEXCOM INC $33.17B 42.1x 15.6%
MDLN Medline Inc. $31.35B 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $23.93B 50.1x 6.3%
SOLV Solventum Corp $15.61B 10.3x 0.9%